By Shankari Swaminathan | Spectrum
“Net-zero by 2040.”
“Carbon-neutral operations.”
These commitments now populate annual reports, investor decks, and ESG disclosures across the global pharmaceutical industry. Yet behind the declarative confidence lies a sector governed not just by intent, but by thermodynamics, regulatory rigidity, and process-critical infrastructure. The central question is no longer whether pharma is committed to decarbonization, but whether its operating model, deeply rooted in sterility, redundancy, and validation, can realistically accommodate it at scale.
The Structural Constraint: When Physics Meets Compliance
Pharmaceutical manufacturing is, by design, energy intensive. Unlike many industrial sectors where production can be throttled, rescheduled, or optimized dynamically, pharma operates within tightly bounded process windows dictated by Good Manufacturing Practices, enforced by regulators such as the U.S. Food and Drug Administration and the European Medicines Agency.
A typical sterile manufacturing facility operates under conditions that inherently drive energy demand:
- Cleanroom classifications (ISO 5 to ISO 8) require high air change rates, often 20 to 60 air changes per hour, maintained continuously
- HVAC systems account for 40 percent to 65 percent of total facility energy consumption
- Temperature and humidity controls must remain within narrow bands, often ±2°C and ±5 percent RH
- Purified Water (PW) and Water for Injection (WFI) systems require continuous circulation at elevated temperatures to prevent microbial growth
- Cold chain infrastructure, especially for biologics and vaccines, adds another layer of continuous energy draw
From a thermodynamic standpoint, these systems are not optional overheads. They are intrinsic to product quality and patient safety. Any attempt to reduce energy consumption must therefore operate within a narrow tolerance band, where deviation risks batch rejection, regulatory non-compliance, or worse, compromised patient outcomes.
The Embedded Carbon Problem: Legacy Infrastructure
In markets such as India, the decarbonization challenge is compounded by legacy infrastructure. A significant portion of pharmaceutical capacity was built between the late 1990s and early 2010s, an era when:
- Energy efficiency standards were not a primary design driver
- Oversizing of utilities was considered a risk mitigation strategy
- Digital monitoring and real-time optimization were limited or absent
The result is a fleet of facilities with structurally embedded inefficiencies:
- HVAC systems operating at fixed loads irrespective of occupancy
- Chillers and boilers running below optimal load curves
- Compressed air systems with leakage rates exceeding 20 percent in some plants
- Lack of granular energy metering at process or equipment level
Retrofitting such facilities is technically feasible but economically complex. Downtime costs, validation requirements, and requalification protocols often outweigh the perceived benefits of incremental efficiency gains.
The Illusion of Progress: Scope Definitions and Reporting Gaps
A critical nuance in pharma’s net-zero narrative lies in emissions accounting. Most companies report significant reductions in Scope 1 and Scope 2 emissions, driven by:
- Transition to renewable power purchase agreements
- Electrification of certain utility systems
- Energy efficiency upgrades
However, Scope 3 emissions, which often constitute 70 percent to 90 percent of total lifecycle emissions, remain less addressed. These include:
- Upstream raw material synthesis, often highly energy intensive
- Solvent production and disposal
- Packaging materials, particularly plastics and aluminum
- Logistics and cold chain distribution
Without meaningful intervention across the value chain, net-zero claims risk being operationally narrow and strategically incomplete.
Where Real Progress Is Emerging
Despite structural constraints, pockets of measurable progress are emerging, driven less by declarations and more by engineering discipline.
1. Design-Led Decarbonization
New greenfield facilities are increasingly incorporating:
- Right-sizing of cleanrooms, avoiding the traditional tendency to overbuild
- Demand-controlled ventilation, adjusting air changes based on occupancy and particulate load
- High-efficiency particulate air (HEPA) filter optimization, reducing pressure drops
- Daylight integration and thermal envelope improvements, lowering HVAC loads
Advanced computational tools, including Computational Fluid Dynamics simulations, are being used to model airflow and contamination risks more precisely, enabling energy reductions without compromising compliance.
2. Process Intensification and Digitalization
The shift toward continuous manufacturing, endorsed by regulators like the U.S. Food and Drug Administration, offers a pathway to lower energy per unit output.
- Reduced batch changeover losses
- Lower solvent usage
- Smaller equipment footprints
- Improved yield and reduced waste
Digital twins and Manufacturing Execution Systems are enabling real-time monitoring of energy intensity per batch, per unit operation, and per product, allowing for data-driven optimization.
3. Utility-Level Optimization
Incremental gains at the utility level are proving to be among the most effective levers:
- Variable Frequency Drives on fans and pumps
- Heat recovery systems in HVAC and boiler operations
- Advanced Building Management Systems with predictive controls
- Leak detection and correction in compressed air networks
These interventions, while individually modest, can cumulatively reduce facility energy consumption by 10 percent to 25 percent.
The Economic Tension: Cost Versus Carbon
Indian pharmaceutical manufacturers operate within one of the most cost-sensitive global supply chains. Generic drug pricing pressures, tender-based procurement models, and thin operating margins create a structural disincentive for sustainability investments.
Capital allocation decisions are often evaluated on short payback periods, typically under three years. Many decarbonization technologies, particularly deep retrofits or advanced automation systems, exceed this threshold.
This creates a paradox: the industry acknowledges the strategic necessity of sustainability, yet its financial architecture prioritizes immediate cost efficiency over long-term environmental performance.
The Risk of Carbon Lock-In
Perhaps the most consequential challenge is temporal. The pharmaceutical industry is in an expansion phase, with new facilities being commissioned across India, Southeast Asia, and parts of Eastern Europe.
Design decisions made today will define emissions profiles for the next 20 to 30 years. Oversized HVAC systems, suboptimal layouts, and lack of digital infrastructure can lock in inefficiencies that are prohibitively expensive to reverse.
In this context, sustainability is not a retrofit problem. It is a design problem.
Beyond Compliance: The Cultural Shift Required
Achieving net-zero in pharma is not a matter of isolated interventions. It requires a systemic shift across stakeholders:
- Architects must design for operational energy performance, not just regulatory compliance
- Engineers must challenge legacy design heuristics, particularly around redundancy and oversizing
- Quality teams must evolve validation frameworks to accommodate dynamic, energy-efficient operations
- Leadership must reframe sustainability from a reporting obligation to a core operational metric
This transition is as much cultural as it is technical.
Between Aspiration and Engineering Reality
Pharma occupies a unique position in the decarbonization landscape. Its mission is inherently aligned with human well-being, yet its operations are among the most energy constrained and compliance driven.
Net-zero, in this context, cannot be achieved through pledges or reporting frameworks alone. It will be the outcome of thousands of engineering decisions, design optimizations, and operational refinements, executed consistently over decades.
The industry is not stagnant. It is moving, but within the limits imposed by physics, regulation, and economics.
The real measure of progress will not be the ambition of its targets, but the rigor of its execution.
About the Guest Author
Shankari Swaminathan is an architect and pharmaceutical infrastructure specialist, currently associated with Spectrum Pharmatech Consultants Pvt. Ltd., where she contributes to the strategic marketing, design and development of complex manufacturing environments spanning cleanrooms, R&D facilities, and regulated production ecosystems. An Indian Green Building Council (IGBC) Accredited Professional, her work sits at the intersection of pharmaceutical engineering, sustainable design, and operational efficiency, bringing a practitioner’s lens to the industry’s decarbonization challenge. Drawing from on-ground exposure to facility design, HVAC-intensive environments, and compliance-driven project execution, her perspective on net-zero in pharma reflects both the technical constraints and the emerging opportunities to embed sustainability at the design and systems level.
Disclaimer: The views and opinions expressed in this editorial are those of the interviewees and are based on their professional experience in pharmaceutical engineering and sterile manufacturing. They do not necessarily reflect the official views, policies, or positions of Hello Pharma, its management, or its affiliates. Hello Pharma does not endorse or take responsibility for any specific technical, commercial, or regulatory interpretations presented in this article. Readers are encouraged to independently evaluate the information shared, review applicable regulatory guidance, and rely on their own experience, expertise, and professional judgment before making decisions related to equipment selection, system design, validation strategy, or regulatory compliance.
